Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a cash flow conversion efficiency ratio of 0.144x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($118.45 Million) by net assets ($819.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AMRX total liabilities for a breakdown of total debt and financial obligations.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hainan Mining Co Ltd
SHG:601969
|
0.076x |
|
GZ Port
SHG:601228
|
0.010x |
|
Maximus Inc
NYSE:MMS
|
-0.142x |
|
Olav Thon Eien
OL:OLT
|
0.000x |
|
Glanbia PLC
IR:GL9
|
0.020x |
|
ELF Beauty Inc
NYSE:ELF
|
0.051x |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
0.029x |
|
Cactus Inc
NYSE:WHD
|
0.044x |
Annual Cash Flow Conversion Efficiency for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below shows the annual cash flow conversion efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Amneal Pharmaceuticals, Inc. Class A Com (AMRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-44.54 Million | $295.10 Million | -6.626x | -138.37% |
| 2023-12-31 | $20.01 Million | $345.58 Million | 17.269x | +5442.32% |
| 2022-12-31 | $208.93 Million | $65.10 Million | 0.312x | -52.71% |
| 2021-12-31 | $366.97 Million | $241.82 Million | 0.659x | -40.03% |
| 2020-12-31 | $344.93 Million | $379.00 Million | 1.099x | +22248.41% |
| 2019-12-31 | $346.79 Million | $1.71 Million | 0.005x | -98.24% |
| 2018-12-31 | $896.36 Million | $250.23 Million | 0.279x | +144.77% |
| 2017-12-31 | $-375.58 Million | $234.19 Million | -0.624x | +4.65% |
| 2016-12-31 | $-175.94 Million | $115.06 Million | -0.654x | -16.52% |
| 2015-12-31 | $-186.87 Million | $104.88 Million | -0.561x | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more